• Королевский колледж акушеров-гинекологов Великобритании Менеджмент синдрома гиперстимуляции яичников 
До змісту

Королевский колледж акушеров-гинекологов Великобритании Менеджмент синдрома гиперстимуляции яичников 

HEALTH OF WOMAN.2016.7(113):66–72 

Королевский колледж акушеров-гинекологов Великобритании Менеджмент синдрома гиперстимуляции яичников 

Руководство № 5 (Февраль 2016 г. Пересмотр третьего руководства 2006 г.).

Печатается с сокращениями. Адаптировано – С.А. Шурпяк


1. Braat DD, Schutte JM, Bernardus RE, Mooij TM, van Leeuwen FE. Maternal death related to IVF in the Netherlands 1984–2008. Hum Reprod 2010;25:1782–6. http://dx.doi.org/10.1093/humrep/deq080; PMid:20488805

2. Whelan JG 3rd, Vlahos NF. The ovarian hyperstimulation syndrome. Fertil Steril 2000;73:883–96. http://dx.doi.org/10.1016/S0015-0282(00)00491-X

3. Ata B, Tulandi T. Pathophysiology of ovarian hyperstimulation syndrome and strategies for its prevention and treatment. Expert Rev Obstet Gynecol 2009;4:299–311. http://dx.doi.org/10.1586/eog.09.10http://dx.doi.org/10.1586/eog.09.10

4. Mathur RS, Tan BK. British Fertility Society Policy and Practice Committee: prevention of ovarian hyperstimulation syndrome. Hum Fertil (Camb) 2014;17:257–68. http://dx.doi.org/10.3109/14647273.2014.961745; PMid:25380089

5. Evbuomwan IO, Davison JM, Murdoch AP. Coexistent hemoconcentration and hypoosmolality during superovulation and in severe ovarian hyperstimulation syndrome: a volume homeostasis paradox. Fertil Steril 2000;74:67–72. http://dx.doi.org/10.1016/S0015-0282(00)00573-2

6. Evbuomwan IO, Davison JM, Baylis PH, Murdoch AP. Altered osmotic thresholds for arginine vasopressin secre- tion and thirst during superovulation and in the ovarian hyperstimulation syndrome (OHSS): relevance to the pathophysiology of OHSS. Fertil Steril 2001;75:933–41. http://dx.doi.org/10.1016/S0015-0282(01)01704-6

7. Evbuomwan I. The role of osmoregulation in the pathophysiology and management of severe ovarian hyperstimulation syndrome. Hum Fertil (Camb) 2013; 16:162–7. http://dx.doi.org/10.3109/14647273.2013.831996; PMid:24047195

8. Zegers-Hochschild F, Mansour R, Ishihara O, Adamson GD, de Mouzon J, Nygren KG, et al. International Committee for Monitoring Assisted Reproductive Technology: world report on assisted reproductive technology, 2005. Fertil Steril 2014;101:366–78.e14. http://dx.doi.org/10.1016/j.fertnstert.2013.10.005; PMid:24188870

9. Delvigne A, Rozenberg S. Epidemiology and prevention of ovarian hyperstimulation syndrome (OHSS): a review. Hum Reprod Update 2002;8:559–77. http://dx.doi.org/10.1093/humupd/8.6.559; PMid:12498425

10. Kupka MS, Ferraretti AP, de Mouzon J, Erb K, D’Hooghe T, Castilla JA, et al.; European IVF-Monitoring Consortium, for the European Society of Human Reproduction and Embryology (ESHRE).Assisted reproductive technology in Europe, 2010: results generated from European registers by ESHRE. Hum Reprod 2014;29:2099–113. http://dx.doi.org/10.1093/humrep/deu175; PMid:25069504

11. Kawwass JF, Kissin DM, Kulkarni AD, Creanga AA, Session DR, Callaghan WM, et al.; National ART Surveillance System (NASS) Group. Safety of assisted reproductive technology in the United States, 2000-2011. JAMA 2015;313:88–90. http://dx.doi.org/10.1001/jama.2014.14488; PMid:25562272

12. Sridev S, Barathan S. Case report on spontaneous ovarian hyperstimulation syndrome following natural conception associated with primary hypothyroidism. J Hum Reprod Sci 2013;6:158–61. http://dx.doi.org/10.4103/0974-1208.117164; PMid:24082659 PMCid:PMC3778607

13. Al-Inany HG, Youssef MA, Aboulghar M, Broekmans F, Sterrenburg M, Smit J, et al. GnRH antagonists are safer than agonists: an update of a Cochrane review. Hum Reprod Update 2011;17:435. http://dx.doi.org/10.1093/humupd/dmr004; PMid:21646384

14. Mathur RS, Akande AV, Keay SD, Hunt LP, Jenkins JM. Distinction between early and late ovarian hyperstimulation syndrome. Fertil Steril 2000;73:901–7. http://dx.doi.org/10.1016/S0015-0282(00)00492-1

15. Memarzadeh MT. A fatal case of ovarian hyperstimulation syndrome with perforated duodenal ulcer. Hum Reprod 2010;25:808–9. http://dx.doi.org/10.1093/humrep/dep434; PMid:20007616

16. Schenker JG, Weinstein D. Ovarian hyperstimulation syndrome: a current survey. Fertil Steril 1978;30:255–68. http://dx.doi.org/10.1016/S0015-0282(16)43508-9

17. Golan A, Ron-el R, Herman A, Soffer Y, Weinraub Z, Caspi E. Ovarian hyperstimulation syndrome: an update review. Obstet Gynecol Surv 1989;44:430–40. http://dx.doi.org/10.1097/00006254-198906000-00004; PMid:2660037

18. Navot D, Bergh PA, Laufer N. Ovarian hyperstimulation syndrome in novel reproductive technologies: prevention and treatment. Fertil Steril 1992;58:249–61. http://dx.doi.org/10.1016/S0015-0282(16)55188-7

19. Mathur R, Evbuomwan I, Jenkins J. Prevention and management of ovarian hyperstimulation syndrome. Curr Obstet Gynaecol 2005;15:132–8. http://dx.doi.org/10.1016/j.curobgyn.2005.01.003

20. Zosmer A, Katz Z, Lancet M, Konichezky S, Schwartz-Shoham Z. Adult respiratory distress syndrome complicating ovarian hyperstimulation syndrome. Fertil Steril 1987;47:524–6. http://dx.doi.org/10.1016/S0015-0282(16)59069-4

21. Abramov Y, Elchalal U, Schenker JG. Pulmonary manifestations of severe ovarian hyperstimulation syndrome: a multicenter study. Fertil Steril 1999;71: 645–51. http://dx.doi.org/10.1016/S0015-0282(98)00399-9http://dx.doi.org/10.1016/S0015-0282(98)00528-7

22. Al Omari W, Ghazal-Aswad S, Sidky IH, Al Bassam MK. Ovarian salvage in bilaterally complicated severe ovarian hyperstimulation syndrome. Fertil Steril 2011;96:e77–9. http://dx.doi.org/10.1016/j.fertnstert.2011.06.005; PMid:21718996

23. Abramov Y, Elchalal U, Schenker JG. Severe OHSS: An ‘epidemic’ of severe OHSS: a price we have to pay? Hum Reprod 1999;14:2181–3. http://dx.doi.org/10.1093/humrep/14.9.2181

24. Human Fertilisation and Embryology Authority [http://www. hfea.gov.uk/docs/Latest_long_term_data_analysis_report_91-06.pdf.pdf]. Accessed 2015 Oct 23.

25. Knight M, Kenyon S, Brocklehurst P, Neilson J, Shakespeare J, Kurinczuk JJ (Eds.) on behalf of MBRRACE-UK. Saving Lives, Improving Mothers’ Care: Lessons learned to inform future maternity care from the UK and Ireland Confidential Enquiries into Maternal Deaths and Morbidity 2009–2012. Oxford: National Perinatal Epidemiology Unit; 2014 [www.npeu. ox.ac.uk/mbrrace-uk/reports].

26. Human Fertilisation and Embryology Authority [http://www.hfea.gov.uk/ docs/General_Directions_0011_-_Reporting_adverse_ incidents_and_near_misses_V3.pdf]. Accessed 2015 Oct 23.

27. Royal College of Obstetricians and Gynaecologists. Ovarian hyperstimulation syndrome: what you need to know. London: RCOG; 2007 [https://www.rcog.org.uk/ globalassets/documents/patients/patient-information- leaflets/gynaecology/ovarian-hyperstimulation-syndrome. pdf].Accessed 2015 Oct 23.

28. Balasch J, Carmona F, Llach J, Arroyo V, Jovй I, Vanrell JA. Acute prerenal failure and liver dysfunction in a patient with severe ovarian hyperstimulation syndrome. Hum Reprod 1990;5:348–51. PMid:2112558

29. Shrivastav P, Nadkarni P, Craft I. Day care management of severe ovarian hyperstimulation syndrome avoids hospitalization and morbidity. Hum Reprod 1994;9:812–4. PMid:7929727

30. Lincoln SR, Opsahl MS, Blauer KL, Black SH, Schulman JD. Aggressive outpatient treatment of ovarian hyperstimu-lation syndrome with ascites using transvaginal culdocentesis and intravenous albumin minimizes hospitalization. J Assist Reprod Genet 2002;19:159–63. http://dx.doi.org/10.1023/A:1014828027282; PMid:12036082 PMCid:PMC3455652

31. Smith LP, Hacker MR, Alper MM. Patients with severe ovarian hyperstimulation syndrome can be managed safely with aggressive outpatient transvaginal paracentesis. Fertil Steril 2009;92:1953–9. http://dx.doi.org/10.1016/j.fertnstert.2008.09.011; PMid:18976762

32. Shukla U, Deval B, Hamoda H, Savvas M, Narvekar N. A programme of outpatient surveillance for women at risk of severe OHSS following IVF: a prospective follow-up review of 99 cases. Hum Fertil (Camb) 2011;14 Suppl 1:7.

33. Royal College of Obstetricians and Gynaecologists. Reducing the Risk of Venous Thromboembolism during Pregnancy and the Puerperium. Green-top Guideline No. 37a. London: RCOG; 2015.

34. Lainas GT, Kolibianakis EM, Sfontouris IA, Zorzovilis IZ, Petsas GK, Tarlatzi TB, et al. Outpatient management of severe early OHSS by administration of GnRH antagonist in the luteal phase: an observational cohort study. Reprod Biol Endocrinol 2012;10:69. http://dx.doi.org/10.1186/1477-7827-10-69; PMid:22938051 PMCid:PMC3489837

35. Rollene NL, Amols MH, Hudson SB, Coddington CC. Treatment of ovarian hyperstimulation syndrome using a dopamine agonist and gonadotropin releasing hormone antagonist: a case series. Fertil Steril 2009;92:1169.e15–17. http://dx.doi.org/10.1016/j.fertnstert.2009.05.062; PMid:19608177

36. Baumgarten M, Polanski L, Campbell B, Raine-Fenning N. Do dopamine agonists prevent or reduce the severity of ovarian hyperstimulation syndrome in women undergoing assisted reproduction? A systematic review and meta-analysis. Hum Fertil (Camb) 2013;16:168–74. http://dx.doi.org/10.3109/14647273.2013.833348; PMid:24047196

37. Nouri K, Tempfer CB, Lenart C, Windischbauer L, Walch K, Promberger R, et al. Predictive factors for recovery time in patients suffering from severe OHSS. Reprod Biol 4–6. Endocrinol 2014;12:59.

38. Practice Committee of the American Society for Reproductive Medicine. Ovarian hyperstimulation syndrome. Fertil Steril 2008;90 Suppl 5:S188–93. http://dx.doi.org/10.1016/j.fertnstert.2008.08.034; PMid:19007627

39. Fбbregues F, Balasch J, Manau D, Jimйnez W, Arroyo V, Creus M, et al. Haematocrit, leukocyte and platelet counts and the severity of the ovarian hyperstimulation syndrome. Hum Reprod 1998;13:2406–10. http://dx.doi.org/10.1093/humrep/13.9.2406; PMid:9806258

40. Nowicka MA, Fritz-Rdzanek A, Grzybowski W, Walecka I, Niemiec KT, Jakimiuk AJ. C-reactiveproteinastheindicator of severity in ovarian hyperstimulation syndrome. Gynecol Endocrinol 2010;26:399–403. http://dx.doi.org/10.3109/09513591003632266; PMid:20170348

41. Maslovitz S, Jaffa A, Eytan O, Wolman I, Many A, Lessing JB, et al. Renal blood flow alteration after paracentesis in women with ovarian hyperstimulation. Obstet Gynecol 2004;104:321–6. http://dx.doi.org/10.1097/01.AOG.0000129956.97012.0d; PMid:15292006

42. Ferraretti AP, Gianaroli L, Diotallevi L, Festi C, Trounson A. Dopamine treatment for severe ovarian hyperstimulation syndrome. Hum Reprod 1992;7:180–3. PMid:1577929

43. Tsunoda T, Shibahara H, Hirano Y, Suzuki T, Fujiwara H, Takamizawa S, et al. Treatment for ovarian hyperstimu- lation syndrome using an oral dopamine prodrug, docarpamine. Gynecol Endocrinol 2003;17:281–6. http://dx.doi.org/10.1080/713603291http://dx.doi.org/10.1080/gye.; PMid:14503971

44. Delvigne A, Rozenberg S. Review of clinical course and treatment of ovarian hyperstimulation syndrome (OHSS). Hum Reprod Update 2003;9:77–96. http://dx.doi.org/10.1093/humupd/dmg005; PMid:12638783

45. Raziel A, Friedler S, Schachter M, Strassburger D, Bukovsky I, Ron-El R. Transvaginal drainage of ascites as an alternative to abdominal paracentesis in patients with severe ovarian hyperstimulation syndrome, obesity, and generalized edema. Fertil Steril 1998;69:780–3. http://dx.doi.org/10.1016/S0015-0282(98)00003-X

46. Ozgun MT, Batukan C, Oner G, Uludag S, Aygen EM, Sahin Y. Removal of ascites up to 7.5 liters on one occasion and 45 liters in total may be safe in patients with severe ovarian hyperstimulation syndrome. Gynecol Endocrinol 2008;24:656–8. http://dx.doi.org/10.1080/09513590802342882; PMid:19031224

47. Royal College of Obstetricians and Gynaecologists. Management of Ascites in Ovarian Cancer Patients. Scientific Impact Paper No. 45. London: RCOG; 2014.

48. Grossman LC, Michalakis KG, Browne H, Payson MD, Segars JH. The pathophysiology of ovarian hyper-stimulation syndrome: an unrecognized compartment syndrome. Fertil Steril 2010;94:1392–8. http://dx.doi.org/10.1016/j.fertnstert.2009.07.1662; PMid:19836016 PMCid:PMC3124341

49. Koike T, Araki S, Minakami H, Ogawa S, Sayama M, Shibahara H, et al. Clinical efficacy of peritoneovenous shunting for the treatment of severe ovarian hyperstimulation syndrome. Hum Reprod 2000;15: 113–17. http://dx.doi.org/10.1093/humrep/15.1.113; PMid:10611198

50. Zhang Q, Xia L, Gao G. A new effective method in the treatment of severe ovarian hyperstimulation syndrome. Iran J Reprod Med 2012;10:589–94. PMid:25246931 PMCid:PMC4169854

51. Rova K, Passmark H, Lindqvist PG. Venous thrombo- embolism in relation to in vitro fertilization: an approach to determining the incidence and increase in risk in successful cycles. Fertil Steril 2012;97:95–100. http://dx.doi.org/10.1016/j.fertnstert.2011.10.038; PMid:22118992

52. ESHRE Capri Workshop Group.Venous thromboembolism in women: a specific reproductive health risk. Hum Reprod Update 2013;19:471–82. http://dx.doi.org/10.1093/humupd/dmt028; PMid:23825156

53. Gelbaya TA. Short and long-term risks to women who conceive through in vitro fertilization. Hum Fertil (Camb) 2010;13:19–27. http://dx.doi.org/10.3109/14647270903437923; PMid:19929571

54. Gorkemli H, Camus M, Clasen K. Adnexal torsion after gonadotrophin ovulation induction for IVF or ICSI and its conservative treatment. Arch Gynecol Obstet 2002;267. http://dx.doi.org/10.1007/s00404-001-0251-x

55. Cupisti S, Emran J, Mueller A, Dittrich R, Beckmann MW, Binder H. Course of ovarian hyperstimulation syndrome in 19 intact twin pregnancies after assisted reproduction techniques, with a case report of severe thromboem- bolism. Twin Res Hum Genet 2006;9:691–6. http://dx.doi.org/10.1375/twin.9.5.691; PMid:17032552

56. Amarin ZO. Bilateral partial oophorectomy in the management of severe ovarian hyperstimulation syndrome. An aggressive, but perhaps life-saving procedure. Hum Reprod 2003;18:659–64. http://dx.doi.org/10.1093/humrep/deg116; PMid:12660253

57. Bellver J, Escudero E, Pellicer A. Bilateral partial oophorectomy in the management of severe ovarian hyperstimulation syndrome (OHSS): ovarian mutilating surgery is not an option in the management of severe OHSS. Hum Reprod 2003;18:1363–7. http://dx.doi.org/10.1093/humrep/deg285; PMid:12832357

58. Mathur RS, Jenkins JM. Is ovarian hyperstimulation syndrome associated with a poor obstetric outcome? BJOG 2000;107:943–6. http://dx.doi.org/10.1111/j.1471-0528.2000.tb10393.x; PMid:10955422

59. Papanikolaou EG, Tournaye H, Verpoest W, Camus M, Vernaeve V, Van Steirteghem A, et al. Early and late ovarian hyperstimulation syndrome: early pregnancy outcome and profile. Hum Reprod 2005;20:636–41. http://dx.doi.org/10.1093/humrep/deh638; PMid:15576388

60. Courbiere B, Oborski V, Braunstein D, Desparoir A, Noizet A, Gamerre M. Obstetric outcome of women with in vitro fertilization pregnancies hospitalized for ovarian hyperstimulation syndrome: a case-control study. Fertil Steril 2011;95:1629–32. http://dx.doi.org/10.1016/j.fertnstert.2010.12.015; PMid:21215968

61. Haas J, Yinon Y, Meridor K, Hershko-Klement A, Orvieto R, Schiff E, et al. Is severe ovarian hyperstimulation syndrome associated with adverse pregnancy outcome? Evidence from a large case-control study. Am J Obstet Gynecol 2014;210 Suppl 1:S329–30. http://dx.doi.org/10.1016/j.ajog.2013.10.707